A Multi-Center Phase I/II Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

Trial Profile

A Multi-Center Phase I/II Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Vorinostat (Primary) ; Cyclophosphamide; Etoposide; Filgrastim; Pegfilgrastim; Prednisone; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 07 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017 as reported by Clinicaltrials.gov record.
    • 07 Mar 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017 as reported by Clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top